Your browser is no longer supported. Please, upgrade your browser.
Settings
RFL Rafael Holdings, Inc. daily Stock Chart
RFL [NYSE]
Rafael Holdings, Inc.
Index- P/E- EPS (ttm)-0.06 Insider Own1.30% Shs Outstand14.18M Perf Week-4.74%
Market Cap196.68M Forward P/E- EPS next Y- Insider Trans- Shs Float9.50M Perf Month-15.94%
Income-0.80M PEG- EPS next Q- Inst Own39.40% Short Float0.60% Perf Quarter60.16%
Sales4.50M P/S43.71 EPS this Y- Inst Trans-0.39% Short Ratio1.44 Perf Half Y53.09%
Book/sh8.81 P/B1.57 EPS next Y- ROA-2.70% Target Price- Perf Year-
Cash/sh1.04 P/C13.29 EPS next 5Y- ROE-3.00% 52W Range3.05 - 19.93 Perf YTD74.91%
Dividend- P/FCF- EPS past 5Y- ROI-9.20% 52W High-30.41% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low354.75% ATR0.83
Employees14 Current Ratio13.00 Sales Q/Q0.00% Oper. Margin- RSI (14)38.20 Volatility4.76% 5.66%
OptionableYes Debt/Eq0.13 EPS Q/Q-61.20% Profit Margin-73.50% Rel Volume0.23 Prev Close14.01
ShortableYes LT Debt/Eq0.13 EarningsMar 12 AMC Payout- Avg Volume39.44K Price13.87
Recom- SMA20-8.09% SMA50-10.00% SMA20031.91% Volume8,891 Change-1.00%
Mar-12-19 04:30PM  Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results PR Newswire +7.34%
Mar-08-19 07:30AM  Rafael Holdings to Report Second Quarter Fiscal Year 2019 Results PR Newswire
Mar-04-19 11:15AM  Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer. GlobeNewswire
Feb-07-19 08:55AM  Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancers T-Cell Lymphoma Dream Team Research Grant GlobeNewswire
Jan-23-19 05:30PM  Rafael Holdings Acquires Majority Stake in Rafael Pharma PR Newswire -8.27%
Jan-17-19 08:00AM  Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium GlobeNewswire +12.95%
Jan-15-19 08:26AM  Old West Investment Management 4th Quarter 2018 Commentary GuruFocus.com +6.19%
Jan-10-19 11:00AM  EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire +30.00%
08:00AM  EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer GlobeNewswire
Jan-09-19 01:15PM  UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia GlobeNewswire
08:00AM  Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer GlobeNewswire
Jan-08-19 08:00AM  Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia GlobeNewswire
Jan-07-19 08:00AM  Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-18 08:00AM  Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire +5.76%
Dec-10-18 04:49PM  Rafael Holdings Reports First Quarter Fiscal Year 2019 Results PR Newswire
Dec-06-18 03:38PM  Rafael Holdings to Report First Quarter Fiscal Year 2019 Results PR Newswire
Dec-05-18 10:00PM  Rafael Holdings to Present at LD Micro Investor Conference PR Newswire
Nov-29-18 09:10AM  Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire
Nov-06-18 08:55AM  Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613 GlobeNewswire
Oct-15-18 09:05AM  Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-09-18 08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-05-18 08:30AM  Rafael Holdings to Report Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
Sep-21-18 12:45PM  Rafael Holdings to Present at Sidoti Fall 2018 Investor Conference PR Newswire
Sep-07-18 08:30AM  Rafael Holdings Increases Stake in Rafael Pharma PR Newswire
Aug-16-18 10:55AM  Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL) GlobeNewswire
Aug-13-18 11:15AM  Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma GlobeNewswire
Jul-09-18 10:39AM  5 Spinoff Stocks That Outperform Their Parents InvestorPlace
Jul-06-18 08:30AM  Rafael Holdings to Ring the NYSE Opening Bell PR Newswire
Jun-11-18 08:30AM  Rafael Holdings Reports Third Quarter Fiscal Year 2018 Results PR Newswire
Jun-07-18 03:12PM  Rafael Holdings to Report Third Quarter Fiscal Year 2018 Results PR Newswire
May-17-18 09:47AM  Should You Be Concerned About Rafael Holdings Incs (NYSEMKT:RFL) Investors? Simply Wall St.
Mar-27-18 08:30AM  IDT Completes Spin-Off of Rafael Holdings PR Newswire
Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.